Compare DPZ & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPZ | QGEN |
|---|---|---|
| Founded | 1960 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 10.2B |
| IPO Year | 2004 | 1998 |
| Metric | DPZ | QGEN |
|---|---|---|
| Price | $310.75 | $36.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 8 |
| Target Price | ★ $434.29 | $45.76 |
| AVG Volume (30 Days) | 770.6K | ★ 2.0M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | 2.40% | ★ 7.17% |
| EPS Growth | ★ 5.27 | N/A |
| EPS | ★ 4.13 | N/A |
| Revenue | ★ $4,939,994,000.00 | N/A |
| Revenue This Year | $7.98 | $8.18 |
| Revenue Next Year | $3.97 | $5.71 |
| P/E Ratio | $75.60 | ★ $24.01 |
| Revenue Growth | ★ 4.96 | N/A |
| 52 Week Low | $297.48 | $32.53 |
| 52 Week High | $496.00 | $57.82 |
| Indicator | DPZ | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 56.56 |
| Support Level | $297.48 | $32.85 |
| Resistance Level | $418.07 | $48.53 |
| Average True Range (ATR) | 8.73 | 0.80 |
| MACD | 1.75 | 0.64 |
| Stochastic Oscillator | 48.99 | 94.23 |
Domino's is the world's largest pizza chain, surpassing $20 billion in system sales with over 22,100 stores across more than 90 markets at the end of 2025. Around 33% of its units are in the US. The business is 99% franchised. Domino's operates through three segments: supply chain (60% of revenue), US stores (33%), and international franchises (7%). The firm generates the bulk of its revenue by supplying food to stores in the US and Canada through a vertically integrated network of 25 manufacturing and supply chain facilities, which primarily produce and distribute dough, and collecting brand royalties and marketing fees from franchisees. Domino's also generates revenue from sales at company-owned stores.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).